Oxylipin Quantification in Preclinical Plasma and Tissue: Free and Esterified Pools, SPE Recovery, and Isotope-Dilution LC-MS/MS

Quantitative oxylipin analysis begins by defining the molecular pool that the concentration is intended to represent. Free oxylipins in plasma, total oxylipins released by hydrolysis, and oxylipins retained within selected lipid classes are different measurands. They require different extraction procedures and support different biological interpretations. A larger signal after hydrolysis does not mean that an acute extracellular mediator increased, and a free-oxylipin panel cannot describe the much larger esterified reservoir.

This distinction is especially important in preclinical plasma and tissue studies. Oxylipins derived from linoleic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid span hydroxy, epoxy, dihydroxy, keto, prostanoid, and specialized pro-resolving mediator subclasses. Their abundance, stability, chromatographic selectivity, extraction behavior, and internal-standard coverage are not uniform. A reliable quantitative study therefore treats sample preparation as part of the analytical method rather than as a generic cleanup step.

Measurand Definition for Oxylipin Quantification

The term “oxylipin concentration” is incomplete unless the report states whether the assay measures a free pool, a total pool, or an esterified fraction. Free oxylipins are extracted without deliberate cleavage of their parent lipids. They are often selected when the research question concerns extracellular signaling, acute pathway activation, or rapidly changing mediator release. This pool is analytically demanding because concentrations may be low and because enzymatic generation, platelet activation, degradation, and adsorption can continue after collection.

Total oxylipins are usually measured after hydrolysis releases molecules that were esterified in phospholipids, triacylglycerols, cholesteryl esters, or other lipids. The resulting value combines free and released esterified material. This improves access to a larger reservoir but removes information about the source lipid class. If free and total values are both measured, esterified abundance may be estimated by difference only when the two workflows have compatible recovery, calibration, and uncertainty.

A lipid-class-resolved design adds a fractionation step before hydrolysis. It can test whether an intervention redistributes oxidized fatty-acid products among neutral lipids and specific phospholipid classes, but every added fraction creates another recovery and matrix-effect problem. Direct analysis of intact oxidized lipids preserves more structural context, whereas hydrolysis followed by targeted LC-MS/MS usually provides higher sensitivity for the released oxylipin. The choice depends on whether sensitivity or lipid-carrier information is the primary analytical objective.

The selected pool should be written into the study objective, sample-processing protocol, calibration plan, and result table. A project that requires both acute mediator signaling and reservoir remodeling should treat free and esterified measurements as parallel analytical branches, not as interchangeable technical replicates. A custom oxylipin quantification and pathway profiling workflow can then be scoped around the intended pool and precursor families rather than around the largest possible list of analytes.

Figure 1. Free, total, and lipid-class-associated oxylipins require different preparation routes and answer different biological questions. Hydrolysis increases access to esterified pools but removes the identity of the original carrier lipid unless fractionation precedes cleavage.

Oxylipin Panel Scope Across PUFA Precursors

An oxylipin panel is broader than an arachidonic-acid or eicosanoid panel. In addition to AA-derived prostanoids, leukotrienes, HETEs, EETs, and DHETs, a comprehensive design may include linoleate-derived HODEs, EpOMEs, and DiHOMEs; alpha-linolenate-derived HOTrEs; EPA-derived HEPEs and epoxy metabolites; and DHA-derived HDoHEs, resolvins, protectins, and maresins. These subclasses differ in endogenous concentration, polarity, chemical stability, number of positional or stereochemical isomers, and availability of authentic standards.

Panel breadth should therefore be set by the biological model and the evidence that can be produced for each analyte. Adding more scheduled MRM transitions does not guarantee greater usable coverage. Dense transition windows can reduce dwell time and points across a peak, while poorly resolved isomers can share fragments. Low-abundance targets may also sit below a qualified lower limit of quantification even when a peak is visible. The panel should identify which compounds will be reported quantitatively, which are monitored semi-quantitatively, and which require confirmation in a separate method.

Precursor coverage also affects pathway interpretation. A treatment that changes dietary or medium PUFA availability may alter the amount of substrate without changing the activity of COX, LOX, CYP, or soluble epoxide hydrolase. Measuring selected precursor fatty acids alongside downstream products helps distinguish substrate-pool effects from downstream conversion, although concentration ratios remain indirect pathway indicators rather than enzyme-rate measurements.

Matrix-Specific Quantitative Design for Plasma and Tissue

Plasma and solid tissue cannot share one universal extraction and calibration claim. Plasma presents a relatively homogeneous fluid matrix but contains proteins, phospholipids, lipoproteins, residual platelets, and endogenous oxylipins. Tissue adds regional heterogeneity, variable water and fat content, residual blood, rapid post-excision metabolism, and the need to define a normalization denominator. A protocol that works for 100–200 µL of plasma should not be transferred to liver, brain, adipose tissue, or lung solely by changing the input mass.

Preclinical Plasma

For plasma, the study protocol should fix the animal handling sequence, feeding state, sampling time, collection route, anticoagulant, tube fill, time to centrifugation, centrifugation temperature, plasma aliquoting, and storage. These variables become especially important when 12-LOX products and thromboxane-related readouts are included. Experiments with delayed human blood processing have shown analyte-specific increases in 12-HETE, 14-HDHA, and TXB2 during room-temperature holding, while many other measured oxylipins were comparatively stable. The correct conclusion is not that every analyte has one universal processing deadline; it is that the project's collection window must be standardized and challenged for the panel that drives the biological claim.

Residual platelets can create another source of variability. A nominal plasma sample can differ in platelet content according to centrifugation and transfer procedure. If platelet-sensitive oxylipins are decision-driving endpoints, the protocol should specify whether platelet-poor plasma is required and retain an indicator of hemolysis, lipemia, and processing deviation. Serum represents a coagulation-associated matrix and should not be substituted for plasma midway through a study.

Solid Tissue

For tissue, the interval from termination of circulation to freezing is part of the measurand. The tissue region, dissection temperature, residual blood strategy, and whether the sample is frozen intact or quenched directly into extraction solvent should be predefined. Repeated washing can remove blood-derived signals but can also introduce handling time and wash out extracellular material. Perfusion may be appropriate for some organ-focused questions, but it changes the matrix and should not be treated as a neutral cleanup step.

Homogenization must be performed under conditions that limit warming and uncontrolled oxygen exposure. Internal standards added before homogenization can monitor losses during disruption and extraction, but they do not reconstruct oxylipins that were enzymatically formed or degraded before the standards entered the sample. A delay challenge, antioxidant comparison, or processing-order experiment is more informative when the main concern is ex vivo conversion.

Normalization depends on the biological claim. Wet weight is convenient but is vulnerable to edema, perfusion, fibrosis, and differences in tissue water. Protein content can change with cell composition or treatment. DNA can provide a cell-number-related denominator but does not capture extracellular matrix or multinucleation. The report should provide the primary denominator and, where interpretation is sensitive to that choice, the unnormalized amount or an alternative denominator.

Figure 2. Plasma and tissue have different preanalytical failure modes. Platelet activation and blood-processing delay dominate selected plasma artifacts, whereas ischemic time, regional sampling, residual blood, homogenization, and denominator selection become central in tissue.

Controlling Ex Vivo Formation and Degradation

Cold handling, short processing time, limited light, oxygen control, antioxidants, metal chelators, and enzyme inhibitors do not solve the same problem. Cooling slows many reactions but does not stop them instantaneously. Radical-chain antioxidants limit selected non-enzymatic oxidation reactions. Chelators reduce metal-catalyzed oxidation. COX, LOX, phospholipase, and epoxide-hydrolase inhibitors affect selected enzymatic routes. An additive can also alter recovery, chromatography, ionization, or the biological reaction being studied.

Consequently, BHT, indomethacin, or another stabilizer should not be presented as a universal tube additive. The analytical team should define the artifact of concern, select an intervention with an appropriate mechanism, and demonstrate that it improves stability without compromising the target panel. A practical pilot can compare immediate processing with one or more realistic delays, with and without the proposed additive. The readout should include compounds expected to be especially sensitive as well as relatively stable panel members.

Free and total workflows create different artifact risks. In a free-oxylipin assay, delay before protein precipitation or SPE can alter the native pool. In a total-oxylipin assay, hydrolysis releases large quantities of PUFA-associated material, and drying or prolonged exposure can generate new oxidation products. Work on esterified oxylipins has shown that lipid-extraction solvent and cartridge drying can change the apparent profile, including artificial formation of epoxy fatty acids. Hydrolysis conditions must therefore be qualified for recovery, conversion, and repeatability rather than copied from a free-oxylipin method.

For non-enzymatic oxidative products such as isoprostanes, the distinction between in vivo oxidation and oxidation during processing is particularly consequential. When oxidative stress is the endpoint, a dedicated isoprostane quantification method should include stability and blank evidence appropriate to the matrix instead of inferring oxidative stress from a small increase in an incompletely qualified broad-panel feature.

SPE Recovery and Matrix Effect Assessment

SPE is often used to concentrate free oxylipins and remove proteins, phospholipids, salts, and other ion-suppressing components. Cartridge chemistry, sample pH, conditioning, wash solvents, cartridge dryness, elution solvent, evaporation, and reconstitution volume can all change the recovered pattern. A comparative study of six SPE procedures and one liquid-liquid extraction procedure found substantial differences among analyte recovery, endogenous extraction efficiency, and removal of ion-suppressing matrix. No procedure maximized all three properties for every analyte.

This trade-off is obscured when a method reports only “recovery.” Three experiments are needed to separate the main components of sample-preparation performance:

• Extraction recovery compares an analyte spiked before extraction with the same amount spiked after extraction.
• Matrix factor compares a post-extraction spike in matrix with a neat standard at the same nominal amount.
• Process efficiency compares the pre-extraction spike with the neat standard and therefore combines recovery and matrix effect.

These quantities should be calculated by analyte and concentration level. A mean recovery across an entire panel can hide selective losses of epoxy, dihydroxy, keto, or highly polar mediators. High apparent recovery can coexist with strong ion enhancement, and a lower but reproducible recovery may be quantitatively preferable when the internal standard tracks the same behavior. The internal-standard-normalized matrix factor should also be tested across individual matrix lots or representative animals, not only in a pooled extract.

Figure 3. Neat standards, post-extraction spikes, and pre-extraction spikes answer different questions. Together they separate matrix effect from extraction recovery and reveal whether an internal standard corrects the complete sample-preparation process.

Stable-Isotope Dilution and Calibration Strategy

An isotopically labeled analogue is the strongest internal standard when it coextracts, coelutes, and ionizes like the analyte without overlapping the endogenous signal. Broad oxylipin panels rarely have a one-to-one labeled standard for every compound. Assigning a surrogate solely because it belongs to the same pathway is inadequate. The assignment should consider functional group, precursor family, acidity, polarity, retention region, extraction behavior, and observed matrix effect.

The internal standard should normally be introduced before the steps it is intended to correct. Addition before SPE can correct extraction variability and ionization when the analogue behaves comparably. Addition after extraction corrects injection and ionization variability but cannot measure extraction loss. Neither strategy corrects biological conversion that occurred before standard addition. The report should retain the internal-standard mapping and flag targets for which the surrogate shows dissimilar recovery or retention behavior.

Calibration is complicated by endogenous oxylipins in plasma and tissue. A true analyte-free biological matrix may not exist. Options include a surrogate matrix, stripped matrix, standard addition, or background subtraction from a pooled matrix. Each option changes the claim:

• A surrogate matrix simplifies calibration but must reproduce relevant recovery and ionization behavior.
• A stripped matrix may remove endogenous analytes while also changing proteins, phospholipids, and binding behavior.
• Standard addition accounts for the study matrix but consumes sample and is difficult to scale across a large panel.
• Background subtraction in pooled matrix requires stable endogenous concentrations and cannot create a blank below that background.

Calibration range should be analyte-specific. A single nominal range across the panel can place abundant HODEs above the upper limit while low-abundance SPMs remain below the lower limit. Accuracy, precision, selectivity, carryover, dilution integrity, recovery, and matrix effect must be evaluated at concentrations that reflect the expected matrix. A targeted lipidomics project should distinguish a fully calibrated concentration from an internal-standard-normalized peak-area response when authentic calibrators or matrix validation are incomplete.

Isomer Resolution and Quantification Confidence

Many oxylipins share nominal or exact masses and produce related product ions. Positional isomers such as 5-, 8-, 11-, 12-, and 15-HETE cannot be assigned by precursor mass alone. Epoxy and dihydroxy products add regioisomeric pairs, while SPM panels include compounds with closely related retention and fragmentation. Scheduled MRM increases multiplexing capacity, but it does not replace chromatographic selectivity.

A quantitative identity should combine retention time matched to an authentic standard, a quantitative transition, at least one suitable qualifying transition where signal permits, and an ion-ratio rule established in standards and matrix. Peak shape and the number of data points across the chromatographic peak should remain adequate in the scheduled window. When a coeluting interference prevents a selective measurement, the analyte should be reported as unresolved, semi-quantitative, or not quantified rather than forced through a common integration rule.

Low-abundance specialized pro-resolving mediators require particular restraint. A visible feature at the expected retention time is not automatically a quantitative SPM measurement. Recent validated bioanalysis incorporated SPE into the validation and assessed selectivity, specificity, matrix effects, recovery, carryover, accuracy, and precision before assigning matrix-based LLOQs. The same validation requirements should be applied when a study intends to interpret resolvins, protectins, or maresins mechanistically. A dedicated resolvin analysis can be used when the required chromatographic and confirmatory evidence exceeds what a broad panel can deliver.

Analytical Quality Requirements for Preclinical Oxylipin Studies

The final report should make it possible to separate biological variation from collection, extraction, chromatography, and quantification failure. A heatmap of pathway changes is useful only after the underlying analytes have passed predefined analytical checks. Results below the LLOQ should not be converted into apparently precise concentrations, and missing values should not be replaced by a fixed fraction of the LLOQ without showing how that choice affects the conclusion.

At minimum, a quantitative preclinical report should retain:

• the defined measurand for every result: free, total, estimated esterified, lipid-class-associated, or intact oxidized lipid;
• animal model, feeding state, treatment timing, collection order, sample matrix, anticoagulant, processing interval, centrifugation, tissue region, and storage history;
• sample input, extraction route, hydrolysis conditions where applicable, SPE chemistry, internal-standard addition point, and analyte-to-standard mapping;
• calibration matrix, regression and weighting, calibration range, dilution rules, and treatment of endogenous background;
• analyte-level recovery, matrix factor, process efficiency, precision, accuracy, carryover, retention-time, and qualifier-ion findings;
• extraction blanks, solvent blanks, pooled matrix QC, replicate extractions, and any delay or stabilizer challenge used to qualify preanalytics;
• sample-level flags for hemolysis, lipemia, insufficient input, processing deviation, internal-standard failure, or integration review;
• clear separation among not detected, detected below LLOQ, quantified, unresolved isomer, and semi-quantitative findings; and
• both amount and normalization denominator for tissue, with enough information to evaluate whether the denominator changed across groups.

Pathway ratios such as EET/DHET or selected product/precursor relationships can assist interpretation, but they remain compound-pool ratios shaped by synthesis, degradation, transport, esterification, and analytical recovery. They should not be labeled as direct enzyme activity without an experimental design that measures flux or independently validates the enzymatic mechanism.

Quantitative interpretation requires alignment among the molecular pool, precursor coverage, collection model, extraction chemistry, internal-standard assignment, chromatographic selectivity, calibration design, and reporting language. When these elements address the same analytical question, treatment-group differences can be attributed to defined oxylipin pools rather than sample-preparation or data-processing artifacts.

References

1. Ostermann AI, Willenberg I, Schebb NH. Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS. Analytical and Bioanalytical Chemistry. 2015;407:1403-1414. https://doi.org/10.1007/s00216-014-8377-4
2. Yuan ZX, Majchrzak-Hong S, Keyes GS, et al. Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry. 2018;410:6009-6029. https://doi.org/10.1007/s00216-018-1222-4
3. Zhang G, Kodani S, Hammock BD. Comprehensive analysis of oxylipins in human plasma using reversed-phase liquid chromatography-triple quadrupole mass spectrometry with heatmap-assisted selection of transitions. Analytical and Bioanalytical Chemistry. 2019;411:367-385. https://doi.org/10.1007/s00216-018-1446-3
4. Ramsden CE, Yuan ZX, Horowitz MS, et al. Temperature and time-dependent effects of delayed blood processing on oxylipin concentrations in human plasma. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2019;150:31-37. https://doi.org/10.1016/j.plefa.2019.09.001
5. Ostermann AI, Koch E, Rund KM, et al. Targeting esterified oxylipins by LC-MS: Effect of sample preparation on oxylipin pattern. Prostaglandins & Other Lipid Mediators. 2020;146:106384. https://doi.org/10.1016/j.prostaglandins.2019.106384
6. Koch E, Mainka M, Dalle C, et al. Clinical blood sampling for oxylipin analysis: effect of storage and pneumatic tube transport of blood on free and total oxylipin profile in human plasma and serum. Analyst. 2020;145:1447-1458. https://doi.org/10.1039/C9AN01880H
7. Polinski KJ, Armstrong M, Manke J, et al. Collection and storage of human plasma for measurement of oxylipins. Metabolites. 2021;11:137. https://doi.org/10.3390/metabo11030137
8. Chen GY, Zhang Q. Quantification of plasma oxylipins using solid-phase extraction and reversed-phase liquid chromatography-triple quadrupole mass spectrometry. Methods in Molecular Biology. 2021;2306:171-186. https://doi.org/10.1007/978-1-0716-1410-5_12
9. Hofstetter RK, Werner M, Schadel P, et al. Validated bioanalysis of oxylipins confirms specialized pro-resolving mediator formation in vitro and in vivo. Journal of Lipid Research. 2026;67:101075. https://doi.org/10.1016/j.jlr.2026.101075